Nuvectis Pharma, Inc.(NVCT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVCT Nuvectis Pharma, Inc.

盘前交易 07-30 04:41:16 EDT

20.69

+0.87

+4.39%

最高21.29	最低19.75	成交量28.76万
今开19.95	昨收19.82	日振幅7.77%
总市值6.52亿	流通市值4.17亿	总股本3,153万
成交额589.89万	换手率1.43%	流通股本2,018万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVCT","market":"US","secType":"STK","nameCN":"Nuvectis Pharma, Inc.","latestPrice":20.69,"timestamp":1785355200000,"preClose":19.82,"halted":0,"volume":287574,"delay":0,"changeRate":0.04389505549949551,"floatShares":20177171,"shares":31525500,"eps":-1.304517,"marketStatus":"盘前交易","change":0.87,"latestTime":"07-30 04:41:16 EDT","open":19.95,"high":21.29,"low":19.75,"amount":5898913.43832,"amplitude":0.077699,"askPrice":24.8,"askSize":100,"bidPrice":16.71,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.304517,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785418200000},"marketStatusCode":1,"adr":0,"listingDate":1638334800000,"exchange":"NASDAQ","adjPreClose":20.69,"postHourTrading":{"tag":"盘后","latestPrice":21.3,"preClose":20.69,"latestTime":"19:34 EDT","volume":4178,"amount":90080.3,"timestamp":1785368047402,"change":0.61,"changeRate":0.029483,"amplitude":0.075882},"volumeRatio":1.3394449085595077,"impliedVol":2.3207,"impliedVolPercentile":0.832},"requestUrl":"/m/hq/s/NVCT","defaultTab":"news","newsList":[{"id":"1154626649","title":"Nuvectis Pharma新药Ciprocopan (NXP100)获中国批准，用于初治PNH患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1154626649","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154626649?lang=zh_cn&edition=full","pubTime":"2026-07-23 19:31","pubTimestamp":1784806274,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma, Inc. 宣布，其创新药物Ciprocopan (NXP100)已在中国获得市场批准，适用于未经治疗的阵发性睡眠性血红蛋白尿症（PNH）患者。此项批准标志着该疗法在中国市场迈出了关键一步，旨在为初治PNH患者群体提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109490196","title":"Nuvectis Pharma下调销售协议招股说明书金额至500万美元（截至2026年6月29日）- 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1109490196","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109490196?lang=zh_cn&edition=full","pubTime":"2026-06-30 04:15","pubTimestamp":1782764138,"startTime":"0","endTime":"0","summary":"根据向美国证券交易委员会（SEC）提交的最新文件，Nuvectis Pharma, Inc. 已将其销售协议招股说明书中的金额下调至500万美元，此数据截至2026年6月29日。这一调整反映了公司对当前融资计划或资本运作策略的更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645006020","title":"海思科(002653.SZ)与Nuvectis签署HSK42360和HSK39297授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2645006020","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645006020?lang=zh_cn&edition=full","pubTime":"2026-06-23 08:47","pubTimestamp":1782175672,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科 发布公告，公司与美国Nuvectis Pharma,Inc.于近日签订独占许可协议，授予Nuvectis在除大中华区域以外的全球范围内开发、生产和商业化HSK42360项目的独家权利，以及在除大中华、东南亚及印度以外区域的全球范围内开发、生产和商业化HSK39297项目的独家权利。作为对外许可交易对价的一部分，公司将从Nuvectis获得HSK42360和HSK39297项目的授权许可费以及销售提成。目前，HSK42360正在开展I期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0033","NVCT","BK0239","BK0077","BK4139","BK0188","002653","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190851505","title":"Nuvectis Pharma与海思科达成协议：后者将获高达4000万美元首付款及近期款项，并有资格获取总额达14.21亿美元的里程碑付款与分级特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1190851505","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190851505?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:35","pubTimestamp":1782128156,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma, Inc.与海思科医药集团股份有限公司（Haisco Pharmaceutical Group Co.,Ltd.）已达成一项重要合作协议。根据协议条款，海思科将获得总额高达4000万美元的首付款及近期阶段性款项。此外，海思科还有资格在未来基于特定研发、注册及商业化里程碑的实现，获取累计最高达14.21亿美元的额外付款。该协议同时包含分级特许权使用费安排，进一步提升了海思科在合作项目成功商业化后的潜在收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0077","BK0028","BK0239","BK0188","BK4139","BK0033","002653","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130696460","title":"Nuvectis Pharma 协议附带融资条件，要求公司确保资本充足","url":"https://stock-news.laohu8.com/highlight/detail?id=1130696460","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130696460?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:35","pubTimestamp":1782128140,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma, Inc. 达成的一项协议附带了融资前提条件，该条件要求公司必须确保拥有充足的资本来完成相关安排。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168811964","title":"海思科保留NXP100在印度及部分东南亚地区的权益，Nuvectis Pharma, Inc. 披露合作细节","url":"https://stock-news.laohu8.com/highlight/detail?id=1168811964","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168811964?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:34","pubTimestamp":1782128097,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma, Inc. 宣布，其合作伙伴海思科制药集团将继续持有在研药物NXP100于印度及特定东南亚地区的商业开发与销售权利。此项协议进一步明确了双方在关键新兴市场区域的权益分配，巩固了现有的战略合作框架。NXP100作为一种备受关注的在研疗法，其区域权利的归属对未来的市场布局具有重要影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139","BK0033","BK0077","BK0188","BK0028","BK0239","002653"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145249234","title":"Nuvectis 与海思科医药集团就两款潜在同类最优临床阶段候选药物达成许可协议，拓展中国以外市场权利，实现战略产品组合扩张","url":"https://stock-news.laohu8.com/highlight/detail?id=1145249234","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145249234?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:33","pubTimestamp":1782127988,"startTime":"0","endTime":"0","summary":"Nuvectis 宣布，已与海思科医药集团达成一项许可协议，获得两款潜在同类最优临床阶段候选药物在中国以外市场的商业化权利。此举标志着Nuvectis在战略上对其产品管线进行了重要拓展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147920612","title":"Nuvectis Pharma 宣布将在2026年美国癌症研究协会年会上展示Nxp900","url":"https://stock-news.laohu8.com/highlight/detail?id=1147920612","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147920612?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:01","pubTimestamp":1774958477,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma, Inc. (NVCT) 已确认，其研发的抗癌候选药物Nxp900将于2026年美国癌症研究协会（AACR）年会上进行专题展示。这一安排标志着该药物研发进程中的重要一步，届时相关数据与研究成果将面向全球肿瘤学界公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518222695","title":"Nuvectis Pharma, Inc.盘中异动 股价大涨5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518222695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518222695?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:43","pubTimestamp":1741614229,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时43分，Nuvectis Pharma, Inc.股票出现异动，股价急速上涨5.27%。截至发稿，该股报7.30美元/股，成交量2.9377万股，换手率0.13%，振幅5.48%。Nuvectis Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Trevi Therapeutics, Inc.、Checkpoint Therapeutics, Inc.、Scisparc Ltd.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2382.81%、559.93%、84.17%，振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.，振幅分别为40.24%、28.59%、25.35%。Nuvectis Pharma, Inc.公司简介：Nuvectis Pharma Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214349a26a295e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214349a26a295e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677943","title":"Nuvectis Pharma, Inc.盘中异动 早盘股价大涨5.05%报6.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677943","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516677943?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:43","pubTimestamp":1741099391,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时43分，Nuvectis Pharma, Inc.股票出现波动，股价快速上涨5.05%。截至发稿，该股报6.45美元/股，成交量4611股，换手率0.02%，振幅5.37%。Nuvectis Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.35%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Protagenic Therapeutics, Inc.、Capricor Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1120.39%、1104.72%、461.59%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Hepion Pharmaceuticals, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 ，振幅分别为37.67%、22.25%、21.85%。Nuvectis Pharma, Inc.公司简介：Nuvectis Pharma Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422431196394834&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422431196394834&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516580866","title":"Nuvectis Pharma, Inc.盘中异动 早盘快速跳水5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516580866","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516580866?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:59","pubTimestamp":1741017564,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时59分，Nuvectis Pharma, Inc.股票出现波动，股价大幅跳水5.01%。截至发稿，该股报6.36美元/股，成交量3.0621万股，换手率0.13%，振幅5.98%。Nuvectis Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.51%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Radiopharm Theranostics Limited涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为3027.60%、142.96%、134.56%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为206.20%、70.53%、50.09%。Nuvectis Pharma, Inc.公司简介：Nuvectis Pharma Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303235924989a2605&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303235924989a2605&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516552208","title":"Nuvectis Pharma, Inc.2024财年实现净利润-19.00百万美元，同比增加14.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516552208","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516552208?lang=zh_cn&edition=full","pubTime":"2025-03-02 00:01","pubTimestamp":1740844860,"startTime":"0","endTime":"0","summary":"3月2日，Nuvectis Pharma, Inc.公布财报，公告显示公司2024财年净利润为-19.00百万美元，同比增加14.65%；其中营业收入为0.00美元，每股基本收益为-1.11美元。从资产负债表来看，Nuvectis Pharma, Inc.总负债8.89百万美元，其中短期债务0.00美元，资产负债比为2.10，流动比率为2.10。机构评级：截至2025年3月2日，当前有3家机构对Nuvectis Pharma, Inc.目标价做出预测，其中目标均价为16.33美元，其中最低目标价为11.00美元，最高目标价为20.00美元。其产品线包括NXP800、NXP900。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000118abe2c59a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000118abe2c59a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514856197","title":"Nuvectis Pharma, Inc.盘中异动 早盘急速上涨6.21%报7.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856197","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514856197?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:35","pubTimestamp":1740580504,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时35分，Nuvectis Pharma, Inc.股票出现异动，股价快速拉升6.21%。截至发稿，该股报7.36美元/股，成交量2350股，换手率0.01%，振幅0.00%。Nuvectis Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。其相关个股中，Sab Biotherapeutics Inc C/Wts 22/10/2026 、Channel Therapeutics Corporation、Immunoprecise Antibodies Ltd.涨幅较大，Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为127.52%、95.24%、76.83%，振幅较大的相关个股有Humacyte Inc C/Wts 27/08/2026 、Nutriband Inc C/Wts 、Channel Therapeutics Corporation，振幅分别为38.41%、17.13%、16.86%。Nuvectis Pharma, Inc.公司简介：Nuvectis Pharma Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223505a254f771&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223505a254f771&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514014642","title":"HC Wainwright & Co.：维持Nuvectis Pharma(NVCT.US)评级，由买入调整至买入评级, 目标价由21.00美元调整至11.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514014642","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514014642?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:52","pubTimestamp":1740502323,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Nuvectis Pharma(NVCT.US)评级，由买入调整至买入评级, 目标价由21.00美元调整至11.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26005248385931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514012679","title":"Nuvectis Pharma, Inc.盘中异动 临近午盘急速下挫5.03%报6.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514012679","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514012679?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:44","pubTimestamp":1740501845,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时44分，Nuvectis Pharma, Inc.股票出现异动，股价快速下挫5.03%。截至发稿，该股报6.99美元/股，成交量4.2608万股，换手率0.19%，振幅4.76%。Nuvectis Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.07%。其相关个股中，Organovo Holdings, Inc.、Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1464.35%、1120.54%、931.53%，振幅较大的相关个股有Organovo Holdings, Inc.、Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为241.19%、87.83%、66.67%。Nuvectis Pharma, Inc.公司简介：Nuvectis Pharma Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260044069892680c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260044069892680c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511137316","title":"Nuvectis Pharma, Inc.盘中异动 大幅拉升5.76%报7.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511137316","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511137316?lang=zh_cn&edition=full","pubTime":"2025-02-15 01:12","pubTimestamp":1739553159,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日01时12分，Nuvectis Pharma, Inc.股票出现异动，股价快速拉升5.76%。截至发稿，该股报7.35美元/股，成交量9.1569万股，换手率0.41%，振幅5.47%。Nuvectis Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.48%。其相关个股中，Moleculin Biotech, Inc.、Allogene Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为2869.01%、749.19%、581.98%，振幅较大的相关个股有Moleculin Biotech, Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为71.65%、70.63%、66.45%。Nuvectis Pharma, Inc.公司简介：Nuvectis Pharma Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215011239abcf28e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215011239abcf28e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510866686","title":"Nuvectis Pharma, Inc.盘中异动 股价大跌5.37%报6.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510866686","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510866686?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:59","pubTimestamp":1739199546,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时59分，Nuvectis Pharma, Inc.股票出现异动，股价急速下挫5.37%。截至发稿，该股报6.35美元/股，成交量9325股，换手率0.04%，振幅6.41%。Nuvectis Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.32%。其相关个股中，Biodexa Pharmaceuticals Plc、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为2265.08%、1425.61%、840.03%，振幅较大的相关个股有Biodexa Pharmaceuticals Plc、Ocean Biomedical, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为59.71%、51.99%、39.57%。Nuvectis Pharma, Inc.公司简介：Nuvectis Pharma Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210225906a240a889&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210225906a240a889&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509729928","title":"Nuvectis Pharma, Inc.盘中异动 急速跳水6.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509729928","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509729928?lang=zh_cn&edition=full","pubTime":"2025-02-08 00:55","pubTimestamp":1738947337,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日00时55分，Nuvectis Pharma, Inc.股票出现波动，股价大幅跳水6.75%。截至发稿，该股报6.75美元/股，成交量8.3906万股，换手率0.37%，振幅5.52%。Nuvectis Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.55%。其相关个股中，Conduit Pharmaceuticals Inc.、Nutriband Inc C/Wts 、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Conduit Pharmaceuticals Inc.、Tonix Pharmaceuticals Holding Corp.、Lipella Pharmaceuticals Inc.较为活跃，换手率分别为5370.19%、168.67%、102.86%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Conduit Pharmaceuticals Inc.、Tonix Pharmaceuticals Holding Corp.，振幅分别为130.43%、67.10%、53.38%。Nuvectis Pharma, Inc.公司简介：Nuvectis Pharma Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208005538987dc724&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208005538987dc724&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508745745","title":"Nuvectis Pharma, Inc.盘中异动 早盘快速上涨5.74%报7.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508745745","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508745745?lang=zh_cn&edition=full","pubTime":"2025-02-04 22:37","pubTimestamp":1738679878,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日22时37分，Nuvectis Pharma, Inc.股票出现波动，股价快速上涨5.74%。截至发稿，该股报7.19美元/股，成交量5745股，换手率0.03%，振幅3.82%。Nuvectis Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Azitra Inc、Evaxion Biotech As、Nutriband Inc C/Wts 涨幅较大，Azitra Inc、Evaxion Biotech As、Enveric Biosciences, Inc.较为活跃，换手率分别为1053.56%、727.07%、191.65%，振幅较大的相关个股有Azitra Inc、Invivyd, Inc.、Coeptis Therapeutics Holdings Inc C/Wts 28/10/2027 ，振幅分别为38.71%、21.70%、21.03%。Nuvectis Pharma, Inc.公司简介：Nuvectis Pharma Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223759a2392a20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223759a2392a20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508396144","title":"Nuvectis Pharma, Inc.盘中异动 早盘快速下挫5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508396144","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508396144?lang=zh_cn&edition=full","pubTime":"2025-02-03 23:00","pubTimestamp":1738594851,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日23时00分，Nuvectis Pharma, Inc.股票出现异动，股价大幅下挫5.03%。截至发稿，该股报6.42美元/股，成交量6351股，换手率0.03%，振幅2.59%。Nuvectis Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.62%。其相关个股中，Gh Research Plc、Invivyd, Inc.、Pasithea Therapeutics Corp C/Wts 12/08/2026 涨幅较大，Cyclerion Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.、Hepion Pharmaceuticals, Inc.较为活跃，换手率分别为245.73%、81.27%、36.01%，振幅较大的相关个股有Invivyd, Inc.、Seastar Medical Holding Corporation、180 Life Sciences Corp C/Wts 07/11/2025，振幅分别为64.33%、33.48%、33.33%。Nuvectis Pharma, Inc.公司简介：Nuvectis Pharma Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020323005298797406&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020323005298797406&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nuvectis.com","stockEarnings":[{"period":"1week","weight":0.0726},{"period":"1month","weight":-0.2748},{"period":"3month","weight":1.4171},{"period":"6month","weight":1.5512},{"period":"1year","weight":1.7368},{"period":"ytd","weight":1.7404}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.015},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.1483},{"period":"ytd","weight":0.0697}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nuvectis Pharma, Inc.于2020年7月27日根据特拉华州法律注册成立。该公司是一家处于临床阶段的生物制药公司，专注于为肿瘤学中具有未满足医疗需求的严重疾病研发精准药物。公司基于对致癌因素的科学研究以及对临床和监管环境的理解进行候选药物的筛选与临床开发，开展针对性的开发项目以推进创新治疗方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.130119},{"month":2,"riseRate":0.75,"avgChangeRate":0.147062},{"month":3,"riseRate":0.6,"avgChangeRate":0.077847},{"month":4,"riseRate":0.8,"avgChangeRate":0.055849},{"month":5,"riseRate":0.8,"avgChangeRate":0.192364},{"month":6,"riseRate":0.2,"avgChangeRate":0.054549},{"month":7,"riseRate":0.4,"avgChangeRate":-0.054911},{"month":8,"riseRate":0.5,"avgChangeRate":-0.005612},{"month":9,"riseRate":0,"avgChangeRate":-0.100626},{"month":10,"riseRate":0.5,"avgChangeRate":-0.011793},{"month":11,"riseRate":0.25,"avgChangeRate":-0.090389},{"month":12,"riseRate":0.75,"avgChangeRate":0.071233}],"exchange":"NASDAQ","name":"Nuvectis Pharma, Inc.","nameEN":"Nuvectis Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvectis Pharma, Inc.(NVCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Nuvectis Pharma, Inc.(NVCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Nuvectis Pharma, Inc.,NVCT,Nuvectis Pharma, Inc.股票,Nuvectis Pharma, Inc.股票老虎,Nuvectis Pharma, Inc.股票老虎国际,Nuvectis Pharma, Inc.行情,Nuvectis Pharma, Inc.股票行情,Nuvectis Pharma, Inc.股价,Nuvectis Pharma, Inc.股市,Nuvectis Pharma, Inc.股票价格,Nuvectis Pharma, Inc.股票交易,Nuvectis Pharma, Inc.股票购买,Nuvectis Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvectis Pharma, Inc.(NVCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Nuvectis Pharma, Inc.(NVCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}